Wegovy 1.5mg GLP-1 Pill, 30 Tablets, for Weight Loss Support

Wegovy 1.5mg Tablets are a prescription-only, once-daily oral GLP-1 receptor agonist treatment containing semaglutide, developed by Novo Nordisk for adults living with obesity or overweight with weight-related health conditions. Designed to support clinically proven and sustainable weight management, Wegovy Pill works with the body's natural mechanisms by reducing appetite, increasing feelings of fullness, and helping individuals consume less over time when combined with healthy lifestyle changes. Built on semaglutide, a molecule supported by more than 8 years of clinical experience in diabetes and weight management, Wegovy Pill offers a convenient oral alternative for individuals who prefer tablets over injections. The treatment follows a gradual dose-escalation approach and is designed for long-term use as part of a comprehensive medical weight management plan.

Taken once daily in the morning on an empty stomach with a small amount of water, Wegovy® Pill fits easily into daily routines. Clinical studies cited by the manufacturer demonstrated meaningful weight reduction, with an average weight loss of approximately 17%, while around one-third of participants achieved weight loss of 20% or more. Wegovy® Pill is intended to be used alongside a balanced diet and increased physical activity under healthcare professional supervision.

Benefits

• Contains semaglutide, a GLP-1 receptor agonist with over 8 years of clinical experience.
• Once-daily tablet format provides an alternative to injectable GLP-1 therapies.
• Works with the body's natural mechanisms to reduce appetite and enhance feelings of fullness.
• Designed to support clinically proven, gradual, and sustainable weight management.
• Can be incorporated into a simple morning routine.
• Intended for long-term use as part of a medical weight management program.
• No injections required, making administration convenient for those with an oral preference.
• Clinical studies reported average weight reduction of approximately 17%, with some participants achieving 20% or greater weight loss.
• Established safety profile consistent with the GLP-1 receptor agonist class.

Suggested Usage : Wegovy 1.5mg Tablets should only be used as prescribed by a healthcare professional. The starting dose consists of one 1.5mg tablet taken once daily in the morning on an empty stomach with up to half a cup of water. Wait at least 30 minutes before eating, drinking, or taking other oral medications. The dose is gradually increased according to the prescribed treatment schedule, with each dose level maintained for approximately 30 days before escalation.

Suitable For

• Adults aged 18 years and above.
• Individuals living with obesity.
• Adults who are overweight and have weight-related health conditions.
• People who prefer oral tablets over injectable treatments.
• Individuals seeking a physician-supervised weight management approach.
• Those committed to combining treatment with balanced nutrition and increased physical activity.
• Not suitable for individuals with hypersensitivity to semaglutide or any formulation components.

Product Specifications